Down day for Tetraphase Pharma


Demonstrating an annoying problem of holding a thinly-traded stock, shares of nano cap Tetraphase Pharmaceuticals (TTPH -13.9%) plummet on a 2x surge in volume, albeit only 354K shares, on no news.

On June 19, the company announced the completion of enrollment of its Phase 3 clinical trial for its lead product candidate eravacycline as a treatment for complicated urinary tract infections.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs